PALI +500% potential according to this analyst

Palisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.

On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.

Market Cap 12.841Mil
52 Week Range 0.76 - 16.02

I think this stock can easily double in price this year.